11q deletion in neuroblastoma: a review of biological and clinical implications

• Published in: Molecular cancer Vol. 16; no. 1; pp. 114 - 12
• Main Authors: Mlakar, Vid, Jurkovic Mlakar, Simona, Lopez, Gonzalo, Maris, John M., Ansari, Marc, Gumy-Pause, Fabienne
• Format: Journal Article
• Language: English
• Published: London BioMed Central 29.06.2017; BioMed Central Ltd; BMC
• Subjects: 11q deletion; Age; Biomedical and Life Sciences; Biomedicine; Bone marrow; Cancer; Cancer Research; Cancer therapies; Chromosome 11; Chromosome Deletion; Chromosomes; Chromosomes, Human, Pair 11 - genetics; Development; Development and progression; DNA Methylation - genetics; Gene expression; Gene mutations; Gene Regulatory Networks; Genetic aspects; Genomes; Haploinsufficiency - genetics; Health aspects; Histology; Humans; Hybridization; Medical prognosis; Metastasis; Molecular modelling; MYCN amplification; Neuroblastoma; Neuroblastoma - genetics; Oncology; Review; Reviews; Studies; Tumors; United States; Switzerland; 11q deletion; Development; MYCN amplification; Neuroblastoma; Metastasis; Review; Cancer
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-017-0686-8

Deletion of the long arm of chromosome 11 (11q deletion) is one of the most frequent events that occur during the development of aggressive neuroblastoma. Clinically, 11q deletion is associated with higher disease stage and decreased survival probability. During the last 25 years, extensive efforts have been invested to identify the precise frequency of 11q aberrations in neuroblastoma, the recurrently involved genes, and to understand the molecular mechanisms of 11q deletion, but definitive answers are still unclear. In this review, it is our intent to compile and review the evidence acquired to date on 11q deletion in neuroblastoma.